

Professor Marco Gerlinger



95-97 Harley Street
London, W1G 6AF
T +44 (0) 20 7317 2500
www.theloc.com

Jennifer Hills
E. gerlingerpa@hcahealthcare.co.uk
T. 0207 317 2562

06 June 2024

Dr. Anita Bhasi
Shrewsbury Road Surgery
Forest Gate
London
E7 8QP

Dear Dr Bhasi,

Name: Mr Jialin Yang
DOB: 6/03/1985 Insurance Policy:
LOC Number: LOC073298 X Number: X3077596 NHS Number: 7178871857
Add.: Flat 48 Cornwell House 13 Ron Leighton Way E6 1EQ
Email: zakkyang@hotmail.com Mobile Phone: 07856226910

Diagnosis and treatment:

Jan 2024: Metastatic (liver) sigmoid adenocarcinoma, MMRp, RAS/BRAF wild type

March 2024: started FOLFIRI chemotherapy while RAS/BRAF status was pending, not a surgical candidate as per ST Barts HPB MDT

April 2024: escalated to FOLFIRI Cetuximab after tumour has been confirmed to be RAS and BRAF wild type, TMB = 6

June 2024: excellent response after 7 cycles of FOLFIRI, cetuximab on CT, MRI liver and PET CT with no new signs of disease.

Referred to Mr Yip, HPV surgeon, for consideration of liver surgery.

I saw Jialin after he has now had a full set of restaging CT, PET and MRI liver scans. This showed an excellent response in all of the liver lesions, as well as the primary tumour and no new sites of disease. In total, the MRI quantified the size of 10 lesions in the liver and the reduction in diameter appears to be at least 50% for each of those. In addition, his tumour marker has now completely normalised. He remains well despite the ongoing chemotherapy, with only some dry skin on his hands and easy bruising. The cetuximab rash he had developed two cycles ago has actually subsided. As discussed in the previous MDT meeting, we will now investigate options for surgery of liver metastases and the primary tumour. I have explained to Jialin that one central liver metastasis is small and can apparently not be reached via surgery. This would likely need intraoperative RFA if it can be identified. He understands that the probability of an overall curative outcome is still very small. However, removal of all visible disease should improve the prognosis, even though further chemotherapy and RFA will be required. I will see him again in two weeks' time to see how cycle eight was tolerated. He will see Mr Yip tomorrow, on the 7th of June.

Yours sincerely,



Professor Marco Gerlinger

cc:

Mr Jialin Yang
Flat 48 Cornwell House
13 Ron Leighton Way
London
E6 1EQ - Via Email

Dr Vincent S Yip